SCHEMBL2660971

SCHEMBL2660971

CC(C)S(=O)(=O)c1cc(OCCc2ccccn2)c2[nH]nc(Nc3cnccn3)c2c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
RIPK2 O43353 1/20 0.33
MAPK1 P28482 4/20 0.33
IGF1R P08069 2/20 0.32
FGFR1 P11362 2/20 0.32
KDR P35968 2/20 0.32
ALDH1A1 P00352 2/20 0.31
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC10 Q969S8 1/20 0.31
HDAC11 Q96DB2 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
HDAC9 Q9UKV0 1/20 0.31
HDAC5 Q9UQL6 1/20 0.31
CSNK2A2 P19784 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2662227 0.84 MEN1 (0.36) MEN1KMT2ARIPK2MAPK1ALDH1A1
SCHEMBL2668292 0.82 MEN1 (0.35) MEN1KMT2ARIPK2CHEK1
SCHEMBL2661771 0.81 MEN1 (0.36) MEN1KMT2AALDH1A1CHEK1HTT
SCHEMBL2661181 0.80 MEN1 (0.32) MEN1KMT2A
SCHEMBL2661190 0.80 JAK2 (0.37) MEN1KMT2AMAPK1IGF1RFGFR1
SCHEMBL16501198 0.78 RIPK2 (0.39) RIPK2GCK
SCHEMBL2661900 0.77 AURKA (0.36) MEN1KMT2AKDR
SCHEMBL2662203 0.76 HSD17B10 (0.36) MEN1KMT2AALDH1A1CHEK1
Trifluoroacetic Acid SCHEMBL2661400 0.72 RIPK2 (0.36) RIPK2MAPK1KDRGCK
SCHEMBL2668191 0.69 GRM4 (0.37) MEN1KMT2AALDH1A1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301155-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-08 US disclosed
US-20110301155-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-08 US disclosed
EP-2157859-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE Takeda Pharmaceutical Company Limited (JP) 2010-03-03 EP disclosed
WO-2008156757-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-24 WO disclosed
WO-2008156757-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301155-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE GCKR, GCK, KHK MEN1 4723/4885KMT2A 2280/4885RIPK2 331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.